Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose priming. (Q30224497)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose priming.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884662%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose priming (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884662%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

influenza vaccine

1 reference

based on heuristic

inferred from title

Markus Alexander Zeitlinger

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884662%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Herwig Kollaritsch

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884662%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Otfried Kistner

7

object named as

Otfried Kistner

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884662%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

5

object named as

Sandor Fritsch

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884662%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Hartmut J Ehrlich

12

object named as

Hartmut J Ehrlich

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884662%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

13

object named as

P Noel Barrett

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884662%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

author name string

Maikel V W van der Velden

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884662%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Gerald Aichinger

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884662%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Eva Maria Pöllabauer

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884662%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Alexandra Löw-Baselli

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884662%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Karima Benamara

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884662%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Markus Müller

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884662%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Timo Vesikari

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884662%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

language of work or name

0 references

publication date

8 August 2012

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884662%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884662%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

30

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884662%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

43

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884662%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

6127-6135

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884662%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Acquisition of human-type receptor binding specificity by new H5N1 influenza virus sublineages during their emergence in birds in Egypt.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

The H5N1 manuscript redaction controversy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Engineered H5N1: a rare time for restraint in science

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

H5N1: Flu transmission work is urgent

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

The NSABB recommendations: rationale, impact, and implications

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Laboratory creation of a highly transmissible H5N1 influenza virus: balancing substantial risks and real benefits

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Science should be in the public domain

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Mammalian-transmissible H5N1 influenza: the dilemma of dual-use research

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Human infection with highly pathogenic H5N1 influenza virus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Update on avian influenza A (H5N1) virus infection in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Probable person-to-person transmission of avian influenza A (H5N1)

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Strategies for mitigating an influenza pandemic

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Development of a mammalian cell (Vero) derived candidate influenza virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Algorithm AS 183: An Efficient and Portable Pseudo-Random Number Generator

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

A clinical trial of a whole-virus H5N1 vaccine derived from cell culture.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Comparison of influenza serological techniques by international collaborative study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

H5N1 whole-virus vaccine induces neutralizing antibodies in humans which are protective in a mouse passive transfer model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Mitigation strategies for pandemic influenza in the United States.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

A heterologous MF59-adjuvanted H5N1 prepandemic influenza booster vaccine induces a robust, cross-reactive immune response in adults and the elderly

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Immunological priming induced by a two-dose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of AS03 adjuvant in adults: results of a randomised single heterologous booster dose study at 15 month

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Molecular programming of B cell memory

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Plasma cells negatively regulate the follicular helper T cell program

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Identifiers

10.1016/J.VACCINE.2012.07.077

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884662%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884662%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30224497&oldid=1602717619"